Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Department of Pharmacology and Toxicology staff profiles

Professor Rhonda Rosengren

PositionProfessor
DepartmentDepartment of Pharmacology and Toxicology
QualificationsBS PhD(Texas A & M)
Research summaryBreast and prostate cancer, nanomedicine, drug metabolism
MembershipsProfessor Rhonda Rosengren is a member of the Auckland Cancer Research Network

Research

Toxicological research in my laboratory involves the identification of novel treatments for various cancers including estrogen receptor negative breast cancer, hormone refractory prostate cancer and ovarian cancer. In conjunction with Dr. Bill Hawkins in the department of Chemistry we are synthesizing novel curcumin derivatives and examining their activity in both in vitro and in vivo models of cancer. We have also discovered new roles for tamoxifen and raloxifene in breast and prostate cancer when given as part of a novel combination therapy or in novel formulations. We also have research collaborations with Dr. Andrew Cridge in the Department of Biochemistry, Dr. Jonathan Bray Head of Small Animal Surgery at Massey University Veterinary School, Dr. Heather Cunliffe in the Department of Pathology and Dr. Mihnea Bostina in the Department of Microbiology and Immunology. The Otago Medical Research Foundation and grants from the University of Otago currently fund our work.


Additional details

In the news

Publications

Rana, Z., Tyndall, J. D. A., Hanif, M., Hartinger, C. G., & Rosengren, R. J. (2021). Cytostatic action of novel histone deacetylase inhibitors in androgen receptor-null prostate cancer cells. Pharmaceuticals, 14, 103. doi: 10.3390/ph14020103

Shakil, M. S., Parveen, S., Rana, Z., Walsh, F., Movassaghi, S., Söhnel, T., Azam, M., … Rosengren, R. J., & Hartinger, C. G. (2021). High antiproliferative activity of hydroxythiopyridones over hydroxypyridones and their organoruthenium complexes. Biomedicines, 9, 123. doi: 10.3390/biomedicines9020123

Hanif, M., Arshad, J., Astin, J. W., Rana, Z., Zafari, A., Movassaghi, S., … Rosengren, R. J., … Hartinger, C. G. (2020). A multitargeted approach: Organorhodium anticancer agent based on vorinostat as a potent histone deacetylase inhibitor. Angewandte Chemie International Edition, 59, 14609-14614. doi: 10.1002/anie.202005758

Shrestha, N., Bland, A. R., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2020). Inhibition of mitogen-activated protein kinase kinase alone and in combination with anaplastic lymphoma kinase (ALK) inhibition suppresses tumor growth in a mouse model of ALK-positive lung cancer. Journal of Pharmacology & Experimental Therapeutics, 374, 134-140. doi: 10.1124/jpet.120.266049

Niloy, M. S., Shakil, M. S., Hossen, M. S., Alam, M., & Rosengren, R. J. (2021). Promise of gold nanomaterials as a lung cancer theranostic agent: A systematic review. International Nano Letters, 11, 111, 93-111. doi: 10.1007/s40089-021-00332-2

Rana, Z., Tyndall, J. D. A., Hanif, M., Hartinger, C. G., & Rosengren, R. J. (2021). Cytostatic action of novel histone deacetylase inhibitors in androgen receptor-null prostate cancer cells. Pharmaceuticals, 14, 103. doi: 10.3390/ph14020103

Journal - Research Article

Shakil, M. S., Parveen, S., Rana, Z., Walsh, F., Movassaghi, S., Söhnel, T., Azam, M., … Rosengren, R. J., & Hartinger, C. G. (2021). High antiproliferative activity of hydroxythiopyridones over hydroxypyridones and their organoruthenium complexes. Biomedicines, 9, 123. doi: 10.3390/biomedicines9020123

Journal - Research Article

Hanif, M., Arshad, J., Astin, J. W., Rana, Z., Zafari, A., Movassaghi, S., … Rosengren, R. J., … Hartinger, C. G. (2020). A multitargeted approach: Organorhodium anticancer agent based on vorinostat as a potent histone deacetylase inhibitor. Angewandte Chemie International Edition, 59, 14609-14614. doi: 10.1002/anie.202005758

Journal - Research Article

Shrestha, N., Bland, A. R., Bower, R. L., Rosengren, R. J., & Ashton, J. C. (2020). Inhibition of mitogen-activated protein kinase kinase alone and in combination with anaplastic lymphoma kinase (ALK) inhibition suppresses tumor growth in a mouse model of ALK-positive lung cancer. Journal of Pharmacology & Experimental Therapeutics, 374, 134-140. doi: 10.1124/jpet.120.266049

Journal - Research Article

Niloy, M. S., Shakil, M. S., Hossen, M. S., Alam, M., & Rosengren, R. J. (2021). Promise of gold nanomaterials as a lung cancer theranostic agent: A systematic review. International Nano Letters, 11, 111, 93-111. doi: 10.1007/s40089-021-00332-2

Journal - Research Other

Rana, Z., Diermeier, S., Hanif, M., & Rosengren, R. J. (2020). Understanding failure and improving treatment using HDAC inhibitors for prostate cancer. Biomedicines, 8(2), 22. doi: 10.3390/biomedicines8020022

Journal - Research Other

Singh, R. J., Martin, C. E., Barr, D., & Rosengren, R. J. (2019). Cucumber peel bead biosorbent for multi-ion decontamination of drinking water collected from a mine region in New Zealand. Environmental Technology, 42(16), 2461-2477. doi: 10.1080/09593330.2019.1703824

Journal - Research Article

Bland, A. R., Shrestha, N., Rosengren, R. J., & Ashton, J. C. (2020). Does crizotinib auto-inhibit CYP3A in vivo? [Brief report]. Pharmacology, 105, 715-718. doi: 10.1159/000506996

Journal - Research Other

Martey, O. N. K., Greish, K., Smith, P. F., & Rosengren, R. J. (2019). A multivariate statistical analysis of the effects of styrene maleic acid encapsulated RL71 in a xenograft model of triple negative breast cancer. Journal of Biological Methods, 6(4). doi: 10.14440/jbm.2019.306

Journal - Research Article

Shrestha, N., Nimick, M., Dass, P., Rosengren, R. J., & Ashton, J. C. (2019). Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. Scientific Reports, 9, 18842. doi: 10.1038/s41598-019-55376-4

Journal - Research Article

Bland, A. R., Bower, R. L., Nimick, M., Hawkins, B. C., Rosengren, R. J., & Ashton, J. C. (2019). Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. European Journal of Pharmacology, 865, 172749. doi: 10.1016/j.ejphar.2019.172749

Journal - Research Article

Smith, R. J., Bower, R. L., Ferguson, S. A., Rosengren, R. J., Cook, G. M., & Hawkins, B. C. (2019). The synthesis of (±)-oxyisocyclointegrin. European Journal of Organic Chemistry, (7), 1571-1573. doi: 10.1002/ejoc.201801751

Journal - Research Article

Mortezaee, K., Salehi, E., Mirtavoos-mahyari, H., Motevaseli, E., Najafi, M., Farhood, B., Rosengren, R. J., & Sahebkar, A. (2019). Mechanisms of apoptosis modulation by curcumin: Implications for cancer therapy. Journal of Cellular Physiology, 234(8), 12537-12550. doi: 10.1002/jcp.28122

Journal - Research Other

Salmaninejad, A., Valilou, S. F., Soltani, A., Ahmadi, S., Abarghan, Y. J., Rosengren, R. J., & Sahebkar, A. (2019). Tumor-associated macrophages: role in cancer development and therapeutic implications. Cellular Oncology, 42, 591-608. doi: 10.1007/s13402-019-00453-z

Journal - Research Other

Chen, S., Nimick, M., Cridge, A. G., Hawkins, B. C., & Rosengren, R. J. (2018). Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer. International Journal of Oncology, 52(2), 579-588. doi: 10.3892/ijo.2017.4207

Journal - Research Article

Martey, O., Nimick, M., Taurin, S., Sundararajan, V., Greish, K., & Rosengren, R. J. (2017). Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer. International Journal of Nanomedicine, 12, 7225-7237. doi: 10.2147/ijn.s148908

Journal - Research Article

More publications...